Compare EPR Properties (EPR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs ResMed Inc. — how do they compare? EPR Properties trades at $54.69 (market cap $4.17B), while ResMed Inc. trades at $228.78 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 7.6× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and ResMed Inc. for 51 Days on average.
| EPR | RMD | |
|---|---|---|
Market Cap | $4.17B | $31.89B |
Volume | 992,716 | 618,314 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $277.88 |
52-Week Low | $48.71 | $182.82 |
Typical Hold Time | 45 Days | 51 Days |
Enterprise Value | $7.68B | $31.24B |
Dividend Yield | 6.84% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.49, up 0.76% today, with a bearish technical signal but oversold oscillators suggesting potential reversal. The REIT shows strong profitability with a 37.66% net income margin and a 6.5% dividend yield, though earnings have been mixed with a recent miss in Q1 2026. Analysts maintain a consensus Buy rating with a $65.50 price target, implying significant upside from current levels.
The outlook is cautiously optimistic given the high dividend yield and discounted valuation, but risks include exposure to interest rate sensitivity and tenant performance in its experiential real estate portfolio. Near-term catalysts include the Q3 2026 earnings release on October 28, 2026, which could validate the company's growth trajectory amid a challenging macro environment.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
